BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
What's Your Reaction?
